GlucoTrack Inc (GCTK)vsEli Lilly and Company (LLY)
GCTK
GlucoTrack Inc
$1.82
-29.46%
HEALTHCARE · Cap: $2.04M
LLY
Eli Lilly and Company
$1,183.46
+0.13%
HEALTHCARE · Cap: $1.03T
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 33.5% profit margin vs 0.0%. GCTK trades at a lower P/E of 0.1x. LLY earns a higher WallStSmart Score of 76/100 (B+).
GCTK
Avoid27
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GCTK
The strongest argument for GCTK centers on P/E Ratio, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : GCTK
The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
GCTK profiles as a value stock while LLY is a growth play — different risk/reward profiles.
GCTK carries more volatility with a beta of 0.66 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 27/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlucoTrack Inc
HEALTHCARE · MEDICAL DEVICES · USA
GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?